SG11201903411YA - Anti-p53 antibodies - Google Patents
Anti-p53 antibodiesInfo
- Publication number
- SG11201903411YA SG11201903411YA SG11201903411YA SG11201903411YA SG11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- polypeptide
- agency
- antibodies
- Prior art date
Links
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 102000002933 Thioredoxin Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
- 229940094937 thioredoxin Drugs 0.000 abstract 1
- 108060008226 thioredoxin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617564.8A GB201617564D0 (en) | 2016-10-17 | 2016-10-17 | Anti-p53 antibodies |
| PCT/SG2017/050522 WO2018074978A1 (en) | 2016-10-17 | 2017-10-17 | Anti-p53 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903411YA true SG11201903411YA (en) | 2019-05-30 |
Family
ID=57680660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903411YA SG11201903411YA (en) | 2016-10-17 | 2017-10-17 | Anti-p53 antibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613568B2 (es) |
| EP (1) | EP3526251A4 (es) |
| JP (1) | JP7173964B2 (es) |
| CN (1) | CN110770252A (es) |
| GB (1) | GB201617564D0 (es) |
| SG (1) | SG11201903411YA (es) |
| WO (1) | WO2018074978A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3040675C (en) * | 2016-12-27 | 2024-02-20 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| GB202008688D0 (en) | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN113403286B (zh) * | 2021-06-24 | 2024-01-16 | 新乡学院 | 一种靶向性三展示噬菌体及其制备方法和应用 |
| US20230108717A1 (en) * | 2021-10-05 | 2023-04-06 | The Penn State Research Foundation | Novel methods of creating a protein map and using said map to identify therapeutic targets |
| AU2022415459A1 (en) * | 2021-12-16 | 2024-07-04 | The Johns Hopkins University | Manabodies targeting p53 tumor antigens and methods of using |
| CN114574524A (zh) * | 2022-03-14 | 2022-06-03 | 深圳市体内生物医药科技有限公司 | 一种从全基因组中筛选肝癌抑癌基因的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083709A (en) | 1985-08-21 | 2000-07-04 | Osi Pharmaceuticals, Inc. | Immunoassay for detection of mutant P53 polypeptide in serum |
| ES2264239T3 (es) | 1990-06-27 | 2006-12-16 | Princeton University | Complejo de proteinas p53/p90'. |
| AU1370592A (en) * | 1991-02-01 | 1992-09-07 | Oncogene Science, Inc. | Immunoassay for detection of mutant p53 polypeptide in biological fluids |
| US5646016A (en) * | 1991-02-06 | 1997-07-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules |
| EP0651653B1 (en) * | 1992-07-22 | 2004-03-10 | The Trustees Of Princeton University | p53 VACCINE |
| US20030086935A1 (en) * | 1992-07-22 | 2003-05-08 | Levine Arnold J. | p53 vaccine |
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| ATE437185T1 (de) | 2005-03-25 | 2009-08-15 | Univ Ramot | Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon |
| US8728479B2 (en) * | 2009-03-31 | 2014-05-20 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
| EP3444262A3 (en) | 2011-09-09 | 2019-04-10 | Agency For Science, Technology And Research | P53 activating peptides |
-
2016
- 2016-10-17 GB GBGB1617564.8A patent/GB201617564D0/en not_active Ceased
-
2017
- 2017-10-17 SG SG11201903411YA patent/SG11201903411YA/en unknown
- 2017-10-17 EP EP17861395.6A patent/EP3526251A4/en active Pending
- 2017-10-17 US US16/342,763 patent/US11613568B2/en active Active
- 2017-10-17 WO PCT/SG2017/050522 patent/WO2018074978A1/en unknown
- 2017-10-17 JP JP2019520556A patent/JP7173964B2/ja active Active
- 2017-10-17 CN CN201780078161.4A patent/CN110770252A/zh active Pending
-
2023
- 2023-02-22 US US18/172,773 patent/US20230257457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7173964B2 (ja) | 2022-11-16 |
| US11613568B2 (en) | 2023-03-28 |
| EP3526251A4 (en) | 2020-06-10 |
| WO2018074978A1 (en) | 2018-04-26 |
| US20230257457A1 (en) | 2023-08-17 |
| GB201617564D0 (en) | 2016-11-30 |
| JP2019535241A (ja) | 2019-12-12 |
| US20190248879A1 (en) | 2019-08-15 |
| CN110770252A (zh) | 2020-02-07 |
| EP3526251A1 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903411YA (en) | Anti-p53 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810471YA (en) | T cell expansion | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel |